TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?

Lancet Oncol. 2020 Aug;21(8):1002-1003. doi: 10.1016/S1470-2045(20)30337-5. Epub 2020 Jul 16.

Authors

Emmanuelle Samalin¹, Antoine Adenis²

Affiliations

¹ Department of Medical Oncology, Montpellier Cancer Institute, Montpellier 34298, France; IGF, CNRS, INSERM, Montpellier University, Montpellier, France. Electronic address: emmanuelle.samalin@icm.unicancer.fr.
² Department of Medical Oncology, Montpellier Cancer Institute, Montpellier 34298, France; IRCM, INSERM, Montpellier University, Montpellier, France.

PMID: 32682456
DOI: 10.1016/S1470-2045(20)30337-5

No abstract available

Publication types

Comment

MeSH terms

Cisplatin
Humans
Leucovorin
Oxaliplatin*
Stomach Neoplasms*
Tegafur

Substances

Oxaliplatin
Tegafur
Cisplatin
Leucovorin